Impurity and degradation testing is an important part of pharmaceutical development, control, and release. Understanding impurity sources, degradation pathways, and regulatory expectations can help inform appropriate specifications and analytical approaches for drug substances and drug products.
In this whitepaper, Smithers experts Michael Creese, Helen Lewis, and Michelle Barnett discuss practical considerations and analytical challenges associated with impurity and degradation testing. The discussion explores impurity management across pharmaceutical development, stability, release testing, and commercial product investigations, with consideration of ICH Q3A(R2) and ICH Q3B(R2).
Learn more about the practical considerations involved in pharmaceutical impurity and degradation testing. Download the whitepaper to explore insights from Smithers experts on impurity identification, degradation, analytical methods, E&L-related leachables, and regulatory expectations.